| 查看: 699 | 回复: 1 | |||
pkupku金虫 (正式写手)
|
[交流]
英国伦敦国王学院KCL招收博士生(高分子,生物医学方向)
|
|
感兴趣可联系:Adrian Najer教授本人, adrian.najer@kcl.ac.uk PhD programme candidate positions in antipathogenic nanomedicines or fundamental nanotherapeutic analysis at King’s College London, UK (potential start dates: Fall 2025) Broadly applicable therapeutics for viral and parasi1c diseases are urgently needed. Nanomedicine offers a unique opportunity to create therapeutics that function by inhibiting host cell interactions. The first project I can offer is centred around the synthesis, analysis, and testing of such advanced antipathogenic nanotherapeutics. The second project encompasses detailed analysis of protein fouling on vesicle-type nanomedicines. This phenomenon, also called protein corona formation, is one key factor currently hindering widespread translation of nanomedicines to the clinic. Hence, fundamental studies and incorporating nanomedicine design changes to allow adsorption of preferred proteins but repelling of undesirable components will be part of that second project. There are two suitable PhD schemes open at the moment, CSC (100% at KCL) and KCL-HKU (joint programme, 50% at each location), and I will consider candidates for both. Please indicate in your email which one you are interested in. PhD schemes: - K-CSC (internal deadline 1st January 2025): hHps://www.kcl.ac.uk/study-legacy/funding/kings-china-scholarship-council-phd-scholarship-programme-k-csc - KCL-HKU joint PhD (deadline 2nd March 2025): hHps://www.kcl.ac.uk/study-legacy/funding/joint-phd-scholarship If interested, please send an email + CV to: adrian.najer@kcl.ac.uk hHps://scholar.google.com/cita2ons?user=K7JUcVIAAAAJ&hl=en&oi=ao |
» 猜你喜欢
279分求调剂 一志愿211
已经有16人回复
求调剂一志愿武汉理工大学材料工程(085601)
已经有5人回复
上海电力大学材料防护与新材料重点实验室招收调剂研究生(材料、化学、电化学,环境)
已经有3人回复
急发核心期刊论文
已经有5人回复
291 求调剂
已经有5人回复
298-一志愿中国农业大学-求调剂
已经有11人回复
一志愿南京理工大学085701资源与环境302分求调剂
已经有7人回复
316求调剂
已经有7人回复
材料与化工考研调剂
已经有4人回复
一志愿重庆大学085700资源与环境,总分308求调剂
已经有7人回复
» 本主题相关商家推荐: (我也要在这里推广)

| 1 |
2楼2024-12-08 09:52:02













回复此楼